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Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is
Morphologically Indistinguishable from Other Causes of DAD
Aims: Diffuse alveolar damage (DAD) is a ubiquitous
finding in inpatient coronavirus disease 2019
(COVID-19)-related deaths, but recent reports have
also described additional atypical findings, including
vascular changes. An aim of this study was to assess
lung autopsy findings in COVID-19 inpatients, and in
untreated severe acute respiratory syndrome coron-
avirus 2 (SARS-CoV-2)-positive individuals who died
in the community, in order to understand the relative
impact of medical intervention on lung histology.
Additionally, we aimed to investigate whether
COVID-19 represents a unique histological variant of
DAD by comparing the pathological findings with
those of uninfected control patients.
Methods and results: Lung sections from autopsy
cases were reviewed by three pulmonary pathologists,
including two who were blinded to patient cohort.
The cohorts included four COVID-19 inpatients, four
cases with postmortem SARS-CoV-2 diagnoses who
died in the community, and eight SARS-CoV-2-
negative control cases. DAD was present in all but
one SARS-CoV-2-positive patient, who was asymp-
tomatic and died in the community. Although SARS-
CoV-2-positive patients were noted to have more focal
perivascular inflammation/endothelialitis than control
patients, there were no significant differences in the
presence of hyaline membranes, fibrin thrombi, air-
space organisation, and ‘acute fibrinous and organis-
ing pneumonia’-like intra-alveolar fibrin deposition
between the cohorts. Fibrinoid vessel wall necrosis,
haemorrhage and capillaritis were not features of
COVID-19-related DAD.
Conclusions: DAD is the primary histological manifes-
tation of severe lung disease in COVID-19 patients
who die both in hospital and in the community, sug-
gesting no contribution of hyperoxaemic mechanical
ventilation to the histological changes. There are no
distinctive morphological features with which to con-
fidently differentiate COVID-19-related DAD from
DAD due to other causes.
Keywords: autopsy, COVID, diffuse alveolar damage
Introduction
As the coronavirus disease 2019 (COVID-19) pan-
demic sweeps across nations, there has been a
general lack of consensus in the rapidly expanding
clinical literature about the extent to which acute
respiratory distress syndrome (ARDS) suffered by
patients infected with severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) is distinct from
ARDS due to other causes. Whereas some patients
are described as having typical ARDS, others are
thought to have atypical presentations or to represent
a new pathobiology altogether.1–4 Similarly, whereas
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the pathological descriptions of pulmonary changes
in patients who suffer from fatal COVID-19 apply the
overarching diagnosis of diffuse alveolar damage
(DAD), some authors emphasise peculiarities, such as
prominent fibrinous airspace exudates, variably con-
spicuous lymphocytic infiltrates with descriptions of
endothelialitis, and a range of other vascular changes
that include fibrinoid necrosis of small vessels, haem-
orrhage and vasculitis, and small-vessel and arterial
thrombosis.1,5–9
To our knowledge, uncontrolled case reports and
series of COVID-19-related lung pathology almost
exclusively include patients who die in hospital, often
after prolonged supportive care. As the histological
descriptions of pulmonary changes in COVID-19-re-
lated ARDS come largely from inpatient data, it is
unknown how or whether hyperoxaemic mechanical
ventilation and other medical interventions may
account for some of the histological findings.
Here, we aimed to assess morphological differences
in the lungs of SARS-CoV-2-positive patients who die
in hospital and those who die in the community with-
out premortem diagnoses of COVID-19. Additionally,
to better understand whether COVID-19 represents a
histological variant of DAD, we systematically com-
pared the pathological findings of SARS-CoV-2-posi-
tive patients with those of uninfected control cases.
Materials and methods
P A T I E N T S E L E C T I O N
This autopsy study was exempt from institutional
review board approval. The University of Michigan’s
Wayne County Medical Examiner Office (WCMEO)
performs postmortem questionnaire screening for
COVID-19 on all cases of non-traumatic death that
occur outside of hospital. Screening criteria for SARS-
CoV-2 testing are based on Centers for Disease Con-
trol and Prevention recommendations.10 Testing may
also be pursued when no information surrounding
the death of the deceased is known/available. When
testing criteria are met, SARS-CoV-2 nasopharyngeal
swabs are collected at the time of autopsy and pro-
cessed with real-time reverse transcriptase polymerase
chain reaction (Molecular Simplexa COVID-19 Direct
real-time RT-PCR assay; DiaSorin, Cypress, CA, USA).
Complete and limited postmortem examinations are
performed by American Board of Pathology-certified
forensic pathologists according to standard proce-
dures. Representative sections of tissue, including
lung, are submitted for tissue processing, and haema-
toxylin and eosin-stained slides are made.
Four persons who died in the Wayne county com-
munity, outside of a hospital setting and without
premortem diagnoses of COVID-19, underwent full
autopsies at WCMEO, and were found to have posi-
tive postmortem SARS-CoV-2 test results. Our data-
base of SARS-CoV-2-positive inpatient autopsies
performed at Michigan Medicine’s University Hospital
was queried to identify a cohort that had the best
possible match, by patient demographics, to the
SARS-CoV-2-positive community death cohort. One
patient in our inpatient cohort has been previously
reported.11 Our autopsy databases were then
searched from 1 January 2016 to 31 December
2019 for inpatient and non-hospitalised community
cases diagnosed as ‘diffuse alveolar damage’. As
these deaths occurred prior to the first reported case
of COVID-19 in the USA,12 the cases were consid-
ered to be SARS-CoV-2-negative (subsequently
referred to as the ‘control cohort’). Patients were
excluded if they were lung transplant recipients or
had received extracorporeal membrane oxygenation
during any part of their hospitalisation. Cases with
Pneumocystis pneumonia were also excluded, as the
frothy exudate characteristic of Pneumocystis can
mimic the appearance of intra-alveolar fibrin deposi-
tion. SARS-CoV-2-negative inpatient control cases
were selected on the basis of the best possible match
of ventilator days with the SARS-CoV-2-positive
inpatient cohort. Only four SARS-CoV-2-negative
non-hospitalised community control cases were iden-
tified that met the inclusion criteria, and all cases
were included. Pertinent patient data were collected
for all cases.
H I S T O L O G I C A L A S S E S S M E N T
All lung slides were independently reviewed by three
pulmonary pathologists (K.E.K., C.F.F., and J.L.M.)
without knowledge of the gross findings, including
lung weights. Two reviewers (C.F.F. and J.L.M.) were
blinded to the patient cohorts. Prior to slide review, a
reference image bank was circulated for standardisa-
tion of diagnostic criteria. Reviewers scored the cases
on a 0–3 scale (0 = absent; 1 = rare/focal;
2 = patchy; 3 = diffuse) for each of the following:
hyaline membranes (Figure 1A), fibrin thrombi (Fig-
ure 1B), airspace organisation (Figure 1C), ‘acute fib-
rinous and organising pneumonia’ (AFOP)-like intra-
alveolar fibrin deposition (Figure 1D), acute bron-
chopneumonia (Figure 1E), perivascular inflamma-
tion and/or endothelialitis (Figure 1F,G), fibrinoid
vessel wall necrosis (Figure 1H), and haemorrhage
and/or capillaritis (Figure 1I). Histological diagnoses
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were rendered in all cases, and other pathological
findings noted.
Results
P A T I E N T C H A R A C T E R I S T I C S
Patient characteristics for the SARS-CoV-2-positive
inpatient and untreated, community death cohorts
are shown in Tables 1 and 2, respectively. Fever and
cough were the most common presenting complaints
in the SARS-CoV-2-positive inpatient cohort, whereas
dyspnoea was more frequently reported in the SARS-
CoV-2-positive community cohort (Table 3). Diabetes,
chronic lung disease and cardiovascular disease were
the most common underlying health conditions in all
SARS-CoV-2-positive cases. Obesity was also com-
mon, with five of eight SARS-CoV-2-positive cases
considered to be obese [body mass index (BMI) of
≥30], and, of these, two were severely obese (BMI of
≥40). Three of the deceased in the non-hospitalised
community cohort died at home; the fourth died in
prison, where he reported no symptoms.
The inpatient control cohort was composed of four
females, two black and two white, ranging in age
from 22 years to 80 years (average, 53 years). Venti-
lator days ranged from zero to 16. All patients died of
clinical ARDS. Two patients had underlying sepsis,
including one with polymicrobial bacteraemia follow-
ing acute cholecystitis, and one with candidaemia.
One patient had acute exacerbation of idiopathic
bronchiectasis and pneumonia, and one suffered an
acute intraparenchymal brain haemorrhage. The
community death control cohort consisted of two
white males, one black female, and one white female,




Figure 1. Standard reference image bank. A, Hyaline membranes. B, Fibrin thrombus. C, Airspace organisation. D, ‘Acute fibrinous and
organising pneumonia’-like intra-alveolar fibrin. E, Acute bronchopneumonia. F, Perivascular inflammation. G, Endothelialitis. H, Fibrinoid
vessel wall necrosis. I, Haemorrhage and capillaritis.
© 2020 John Wiley & Sons Ltd, Histopathology, 77, 570–578.
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natural causes, with primary autopsy findings of DAD
with or without acute bronchopneumonia.
P A T H O L O G I C A L F I N D I N G S
An average of five sections per case (range 3–7) of
lung were submitted at the time of autopsy for SARS-
CoV-2-positive inpatients. The average for inpatient
control cases was 4.8 sections per case (range, 4–5).
The averages for non-hospitalised community cohorts
were 3.8 sections per case (range, 3–5) for SARS-
CoV-2-positive cases, and 3.5 sections per case
(range, 2–5) for SARS-CoV-2-negative control cases.
Definite DAD was identified in all but one (case no.
7) of the SARS-CoV-2-positive cases (Table 4). There
was overall agreement in confirming the presence of
DAD in the control cases. The lung weights for
patients with a consensus diagnoses of DAD ranged
from 620 g to 1600 g for the right lung (normal
average, 300–350 g) and from 640 g to 1350 g for
the left lung (normal average, 250–300 g). The
patient without DAD (case no. 7) had lung weights of
450 g each for the right and left lungs.
Among all cases reviewed (n = 16), there was una-
nimity regarding the presence of hyaline membranes
in 14 cases, and unanimity regarding the extent of
the hyaline membranes in nine cases. Among the
cases without concordance, the majority of disagree-
ments (n = 5) were due to differences in interpreta-
tion of the extent; in two cases (no. 7 and no. 15),
there was lack of agreement on the presence of hya-
line membranes. Case no. 7 was diagnosed as ‘early
DAD’ by one reviewer, who identified focal hyaline
membranes, whereas the other two reviewers did not
see hyaline membranes. Case no. 15 was complicated
by diffuse acute bronchopneumonia. Two reviewers
also reported patchy hyaline membranes and diag-
nosed DAD, whereas one reviewer diagnosed only
acute bronchopneumonia.
Fibrin thrombi, involving small precapillary vessels
and/or muscular arteries, were identified by at least
one reviewer in 13 cases. Fibrin thrombi were not
Table 1. Severe acute respiratory syndrome coronavirus 2-positive inpatient cohort characteristics
Case
Age




















4 63 Female Black 28.2 DM2, HTN, CAD Cough, fever 16 Sarilumab trial†
BMI, body mass index; CAD, coronary artery disease; DM2, type II diabetes; HA, headache; HTN, hypertension; SOB, shortness of breath.
*The patient had a ‘do not intubate’ order.
†The patient was enrolled in a phase II/III randomised, double-blind, placebo-controlled study assessing the efficacy and safety of sarilumab
in hospitalised patients with coronavirus disease 2019. It is unknown whether the patient received sarilumab or placebo.
Table 2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive community cohort characteristics
Case
Age
(years) Sex Race BMI Medical conditions Premortem symptoms
Indication(s) for postmortem SARS-
CoV-2 testing




6 44 Male Black 48.5 None Fever, SOB Symptomatic
7 55 Male Black 34.9 CVD, DM2, chronic renal
failure on HD
None Sick contacts, prisoner
8 67 Male Black 21.7 Drug abuse disorder Unknown Unknown symptoms, contacts, and
travel history
BMI, body mass index; CVD, cardiovascular disease; DM2, type II diabetes; HD, haemodialysis; SOB, shortness of breath.
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identified in one SARS-CoV-2-positive case and two
control cases. There was no difference in the overall
extent of fibrin thrombi identified between SARS-CoV-
2-positive cases and control cases, with an average
extent of 0.9 (on a scale of 0–3) in both aggregated
SARS-CoV-2-positive cases and control cases.
Histological evidence of organising DAD was
reported by at least one reviewer as focal (score 1) or
patchy (score 2) airspace organisation in three of four
SARS-CoV-2-positive inpatients. Airspace organisation
was scored as present by all three reviewers in only
one case (no. 3). In contrast, airspace organisation
was not identified by any reviewers in SARS-CoV-2-
positive community cases.
Interobserver variability was greatest for AFOP-like
intra-alveolar fibrin, which was scored as present by
at least one reviewer in all cases. This feature was
identified by all three reviewers in 11 cases that were
equally distributed across all four cohorts, with una-
nimity regarding extent in six of them. Of the cases
for which there was not a consensus on extent,
reviewers scored four cases as either 1 (focal) or 2
(patchy), and one was scored as 2 (patchy) or 3 (dif-
fuse). For five cases, spread across all four cohorts,
there was lack of agreement on the presence of
AFOP-like intra-alveolar fibrin, but, when scored as
present, it was only a focal finding (score of 1). Over-
all, the extent of fibrin deposition was not appreciably
different between aggregated SARS-CoV-2-positive
cases (average 0.9) and control cases (average 1).
There was more acute bronchopneumonia in
SARS-CoV-2-positive inpatients (average of 1.5) than
in SARS-CoV-2-positive community cases (average of
0.8). Perivascular inflammation was a more common
finding in SARS-CoV-2-positive cases (average of 0.4)
than in control cases (average of <0.1), but, in SARS-
CoV-2-positive cases, it was a focal finding when
identified, and only one case was scored as having
perivascular inflammation by all three reviewers. Fib-
rinoid vessel wall necrosis, haemorrhage and/or capil-
laritis were not features of SARS-CoV-2-positive cases.
Viral cytopathic changes were not seen in any SARS-
CoV-2-positive cases.
Discussion
To our knowledge, this is the first comparison of
autopsy lung findings in SARS-CoV-2-positive medi-
cally managed inpatients and untreated, non-hospi-
talised deceased persons with those in uninfected
historical control cases of DAD. The main limitation
of our study is the small number of cases in each
of the cohorts. Nonetheless, we think our SARS-
CoV-2-positive cases are probably representative of
the broader COVID-19 patient population, as both
hospitalised and non-hospitalised deceased persons
had underlying conditions previously identified as
risk factors for severe disease, including diabetes,
chronic lung disease, cardiovascular disease,13 and
obesity.14
DAD is ubiquitous at autopsy in hospitalised and
non-hospitalised COVID-19 patients. DAD was the
primary abnormality in all hospitalised COVID-19
Table 3. Comparison of severe acute respiratory syndrome










Range (average) 44–67 (55.5) 37–79 (56.3)
<65 3 4
≥65 1 1
Male/female ratio 3:1 2:2
Black/white ratio 4:0 3:1
BMI range (average) 21.7–48.5 (34.7) 18.5–46.6 (31.9)
Presenting/premortem
symptoms
Fever 4 (100) 1 (25)
Cough 4 (100) 1 (25)
Myalgia 3 (75) 1 (25)
Dyspnoea 2 (50) 2 (50)
Headache 2 (50) 0 (0)
GI complaints 1 (25) 1 (25)
None/unknown 0 (0) 2 (25)
Medical conditions
Diabetes 4 (100) 1 (25)
Chronic lung disease 2 (50) 0 (0)
Cardiovascular disease 1 (25) 2 (25)
Immunocompromised
condition
1 (25) 0 (0)
Chronic renal disease 0 (0) 1 (25)
BMI, body mass index; GI, gastrointestinal.
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patients, as previously reported by others.5–9,15,16
DAD was also present in nearly all SARS-CoV-2-posi-
tive deceased persons who died without medical inter-
vention. This suggests that COVID-19-related lung
disease is a common cause of death not only in hospi-
talised patients, but also in those who die in the com-
munity. The single exception was a case that lacked
histomorphological features clearly diagnostic of
DAD. The lung weights were also relatively normal
as compared with all other cases in which DAD was
present. All reviewers noted a focal AFOP-like air-
space exudate, similarly to previous descriptions of
incidental pulmonary findings in patients later diag-
nosed with COVID-19.17 This person was reportedly
asymptomatic prior to being found dead. We con-
clude that he was either an asymptomatic SARS-CoV-
2 carrier or suffered from early preclinical or subclini-
cal COVID-19, for the following reasons: (i) the
absence of significant pulmonary changes; and (ii)
autopsy evidence of hypertensive heart disease, which
probably accounted for his death.
SARS-CoV-2-positive inpatient and non-hospitalised
community cases show no meaningful differences in
lung histology at autopsy. DAD is the primary abnor-
mality in both, with there being little to distinguish
these two populations. Airspace organisation, which
is a finding more typical of the organising phase of
DAD, was seen only in hospitalised COVID-19
patients, indicating that they survived longer with
their lung disease than their non-hospitalised coun-
terparts. Neither SARS-CoV-2-infected cohort showed
fibrinoid vessel wall necrosis, vasculitis/capillaritis or
haemorrhage resembling that previously reported by
others.7–9 We have not observed any of these vascu-
lar changes in other hospital-based COVID-19 patient
autopsies that were not included in this study. Given
the morphological similarity between treated COVID-
19 DAD and COVID-19 DAD in non-hospitalised
patients, we conclude that the DAD seen in the inpa-
tient cohort is directly attributable to viral infection
rather than medical therapies, including those that
may cause hyperoxaemic lung injury.
DAD in SARS-CoV-2-positive patients is histologi-
cally indistinguishable from DAD due to other causes.
Although additional clinical correlation is needed to
understand whether the ARDS experienced by
COVID-19 patients represents a novel subphenotype,
our results suggest that the histological features of
COVID-19-related DAD are not specific, and indicate
that the pathogenesis includes elements common to
other causes of DAD. Fibrin thrombi with an average
score of at least rare/focal (≥1) were seen in five of
eight SARS-CoV-2-positive cases and in four of eight
control cases. Furthermore, we have not observed a
greater incidence of thrombi in other COVID-19 inpa-
tient autopsies. These observations underscore the
original descriptions of DAD, in which fibrin thrombi
were common.18 Indeed, the term DAD was coined to
emphasise the central role of diffuse injury to the
epithelium and endothelium constituting the distal
pulmonary acinus. AFOP-like fibrin also occurred
with similar frequency in all SARS-CoV-2-infected
and uninfected cases. At least focal (mean of ≥1)
AFOP-like changes were identified in five of eight
SARS-CoV-2-positive cases and in six of eight control
cases. This finding was never more than ‘patchy’ in
SARS-CoV-2-positive cases as independently assessed
by three reviewers, including two who were blinded
to cohort assignment. AFOP-like fibrin was extensive
in only a single non-hospitalised case that preceded
the COVID-19 pandemic, supporting the non-specific
nature of this histological finding. Variably prominent
alveolar fibrin deposition was also included in the
original description of DAD,18 further demonstrating
that it is not specific to COVID-19 or any other vari-
ant of DAD. Perivascular inflammation was noted by
at least one reviewer in five of eight SARS-CoV-2-pos-
itive cases as compared with one of eight COVID-19-
negative control cases. When present, this finding
was, at most, focal (mean of ≤1) and of uncertain sig-
nificance with regard to the pathogenesis of COVID-
19-related lung disease. As a diagnostic clue, it is nei-
ther specific nor sufficient to reliably separate COVID-
19 from other causes of DAD. Similar patterns of
inflammation have been described and illustrated
with a variety of terms in other viral pneumonias,
including those caused by coronaviruses, human
parechovirus, respiratory syncytial virus, human
parainfluenza virus 1, and influenza virus.19 This
finding has also been described in non-viral cases of
DAD, further emphasising its non-specific nature.18
We had relatively high rates of concordance for the
presence or absence of most histological features, and
discordance usually involved a difference of only a
single grade (e.g. ‘absent’ versus ‘rare/focal’). The
rates of discordance were randomly distributed across
all four cohorts, and therefore did not significantly
affect the final comparisons. Finally, as the numbers
of lung sections examined were relatively consistent
between cohorts, we think that sampling bias is unli-
kely to explain our results.
In summary, our blinded comparison of SARS-CoV-
2-infected deceased persons affirm previous observa-
tions of DAD as the primary histological manifesta-
tion of severe lung disease in hospitalised COVID-19
patients, and further establishes that this is the
© 2020 John Wiley & Sons Ltd, Histopathology, 77, 570–578.
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primary finding in those who die untreated, in non-
hospital settings. We also demonstrate that the histo-
morphological findings in SARS-CoV-2-infected
patients show substantial overlap with those in
patients who have DAD from other causes, suggesting
common elements in their pathogenesis.
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